$ARNA News S&P 500 back for another crack at m
Post# of 72749
Posted On: 10/21/2014 12:05:17 PM
$ARNA News
S&P 500 back for another crack at major support 12:21 p.m. Jan. 31, 2014 - Michael Ashbaugh
Arena shares surge as marketer doubles sales force for diet drug 12:41 p.m. Oct. 15, 2013 - Russ Britt
Obesity drug makers jockey for position as analysts praise Vivus 1:06 p.m. Oct. 3, 2013 - Russ Britt
Hedge funds are buying these stocks right now 2:46 p.m. July 23, 2013 - Insider Monkey
5 stocks insiders are buying 2:52 p.m. June 7, 2013 - Insider Monkey
6 gut checks before the stock market's opening bell 7:47 a.m. March 7, 2013 - Shawn Langlois
Stocks to watch Monday: Transocean, Stratasys 10:22 a.m. March 4, 2013 - Sue Chang
Arena Pharmaceuticals down 7.4% in premarket 10:11 a.m. Jan. 22, 2013 - Steve Gelsi
What 2012’s winners and losers say about 2013 7:00 a.m. Dec. 14, 2012 - Howard Gold
6 gut checks before the stock market's opening bell 7:50 a.m. Dec. 12, 2012 - Shawn Langlois
4 charts challenging resistance 8:06 a.m. Oct. 16, 2012 - The Trading Deck
Vivus sees EU regulators rejecting diet drug 1:16 p.m. Sept. 21, 2012 - MarketWatch.com
Vivus falls 11% on EU drug approval update 12:07 p.m. Sept. 21, 2012 - Val Brickates Kennedy
Arena rises as Vivus sees anti-obesity setback 8:49 a.m. Sept. 21, 2012 - Greg Morcroft
Vivus says Europe likely to reject obesity drug 8:33 a.m. Sept. 21, 2012 - MarketWatch.com
Orexigen soars 19% on analyst buy rating 1:46 p.m. Sept. 6, 2012 - Val Brickates Kennedy
Arena jumps 12% amid takeover speculation 2:55 p.m. Aug. 14, 2012 - Val Brickates Kennedy
Arena trips Nasdaq short-sale circuit breaker 4:01 p.m. Aug. 1, 2012 - Val Brickates Kennedy
Arena Pharma share drop trips short-sale limit 3:16 p.m. Aug. 1, 2012 - Laura Mandaro
Eisai gears up for launch of Arena's diet drug 10:32 a.m. July 30, 2012 - Val Brickates Kennedy
Orexigen Launches Contrave - Watch For Traction 2:01 p.m. Oct. 20, 2014 - Seeking Alpha
Belviq Sales Dip: What To Watch For Ahead 1:13 p.m. Oct. 17, 2014 - Seeking Alpha
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents 7:05 a.m. Oct. 17, 2014 - TheStreet.com
What To Watch For As Orexigen's Launch Approaches 8:05 a.m. Oct. 16, 2014 - Seeking Alpha
Pfizer Setback Could Help Arena 9:44 a.m. Oct. 15, 2014 - Seeking Alpha
Belviq Sales Rise Almost 5% Week Over Week 12:39 p.m. Oct. 10, 2014 - Seeking Alpha
Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BELVIQ (lorcaserin HCl) CIV In Postgraduate Medicine 10:37 a.m. Oct. 10, 2014 - benzinga.com
Orexigen On A Tear - In The Wrong Direction 1:10 a.m. Oct. 7, 2014 - Seeking Alpha
Belviq Sales Flat - Model Your Expectations 6:44 p.m. Oct. 3, 2014 - Seeking Alpha
A Look At Arena's Other Drug 4:37 p.m. Oct. 3, 2014 - Seeking Alpha
Premature Combination Use Of Belviq And Phentermine Is A Risk 9:27 a.m. Sept. 28, 2014 - Seeking Alpha
Arena Pharmaceuticals (ARNA) on NewsMakers in the Biotech Industry Conference Call Transcript 2:22 p.m. Sept. 26, 2014 - Seeking Alpha
Belviq Sales Benefit From Advertising - Up 2.8% 12:16 p.m. Sept. 26, 2014 - Seeking Alpha
Belviq Advertising Sees Major Push - The Equity May See It As Well 5:25 p.m. Sept. 22, 2014 - Seeking Alpha
Belviq Sales Recover From Holiday Dip 5:06 p.m. Sept. 21, 2014 - Seeking Alpha
A Deeper Look At Belviq And Phentermine - Why Investors Need To Model Expectations 12:08 p.m. Sept. 19, 2014 - Seeking Alpha
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume 10:04 a.m. Sept. 19, 2014 - TheStreet.com
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape 9:11 a.m. Sept. 19, 2014 - Zacks.com
It Takes Less Than 15 Minutes To Buy VVUS Shares! 8:51 a.m. Sept. 19, 2014 - Seeking Alpha
Belviq And Phentermine Study Awes Some Investors - Should It? 10:00 a.m. Sept. 17, 2014 - Seeking Alpha
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 9:30 a.m. Oct. 17, 2014 - PR Newswire - PRF
Global Anti-Obesity Drugs Market 5:07 p.m. Oct. 16, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine 11:36 a.m. Oct. 10, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 8:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 8:40 a.m. Sept. 12, 2014 - PR Newswire - PRF
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 8:00 a.m. Sept. 2, 2014 - PR Newswire - PRF
Post-Earnings Review and Highlights - Arena Pharma 9:30 a.m. Aug. 11, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4:30 a.m. Aug. 1, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 8:00 a.m. July 30, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category 8:00 a.m. July 29, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 8:00 a.m. July 25, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel 8:00 a.m. July 21, 2014 - PR Newswire - PRF
Cannabis Based Healing Products Lead Commercialization For Medical Marijuana Patients - Company Introduces New Edible CBD-Rich Product Line 8:30 a.m. July 16, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office 4:31 p.m. July 15, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV 8:00 a.m. July 10, 2014 - PR Newswire - PRF
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma 7:20 a.m. July 10, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference 8:00 a.m. June 13, 2014 - PR Newswire - PRF
Dosing Initiation, Conferences Participation, Trial Results Publication, and Financial Results - Analyst Notes on Arena, Acceleron Pharma, HealthSouth, The Medicines Company and Taro 5:40 a.m. June 10, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Initiates Phase 1b Clinical Trial of APD334 for Autoimmune Diseases 8:00 a.m. June 3, 2014 - PR Newswire - PRF
S&P 500 back for another crack at major support 12:21 p.m. Jan. 31, 2014 - Michael Ashbaugh
Arena shares surge as marketer doubles sales force for diet drug 12:41 p.m. Oct. 15, 2013 - Russ Britt
Obesity drug makers jockey for position as analysts praise Vivus 1:06 p.m. Oct. 3, 2013 - Russ Britt
Hedge funds are buying these stocks right now 2:46 p.m. July 23, 2013 - Insider Monkey
5 stocks insiders are buying 2:52 p.m. June 7, 2013 - Insider Monkey
6 gut checks before the stock market's opening bell 7:47 a.m. March 7, 2013 - Shawn Langlois
Stocks to watch Monday: Transocean, Stratasys 10:22 a.m. March 4, 2013 - Sue Chang
Arena Pharmaceuticals down 7.4% in premarket 10:11 a.m. Jan. 22, 2013 - Steve Gelsi
What 2012’s winners and losers say about 2013 7:00 a.m. Dec. 14, 2012 - Howard Gold
6 gut checks before the stock market's opening bell 7:50 a.m. Dec. 12, 2012 - Shawn Langlois
4 charts challenging resistance 8:06 a.m. Oct. 16, 2012 - The Trading Deck
Vivus sees EU regulators rejecting diet drug 1:16 p.m. Sept. 21, 2012 - MarketWatch.com
Vivus falls 11% on EU drug approval update 12:07 p.m. Sept. 21, 2012 - Val Brickates Kennedy
Arena rises as Vivus sees anti-obesity setback 8:49 a.m. Sept. 21, 2012 - Greg Morcroft
Vivus says Europe likely to reject obesity drug 8:33 a.m. Sept. 21, 2012 - MarketWatch.com
Orexigen soars 19% on analyst buy rating 1:46 p.m. Sept. 6, 2012 - Val Brickates Kennedy
Arena jumps 12% amid takeover speculation 2:55 p.m. Aug. 14, 2012 - Val Brickates Kennedy
Arena trips Nasdaq short-sale circuit breaker 4:01 p.m. Aug. 1, 2012 - Val Brickates Kennedy
Arena Pharma share drop trips short-sale limit 3:16 p.m. Aug. 1, 2012 - Laura Mandaro
Eisai gears up for launch of Arena's diet drug 10:32 a.m. July 30, 2012 - Val Brickates Kennedy
Orexigen Launches Contrave - Watch For Traction 2:01 p.m. Oct. 20, 2014 - Seeking Alpha
Belviq Sales Dip: What To Watch For Ahead 1:13 p.m. Oct. 17, 2014 - Seeking Alpha
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents 7:05 a.m. Oct. 17, 2014 - TheStreet.com
What To Watch For As Orexigen's Launch Approaches 8:05 a.m. Oct. 16, 2014 - Seeking Alpha
Pfizer Setback Could Help Arena 9:44 a.m. Oct. 15, 2014 - Seeking Alpha
Belviq Sales Rise Almost 5% Week Over Week 12:39 p.m. Oct. 10, 2014 - Seeking Alpha
Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BELVIQ (lorcaserin HCl) CIV In Postgraduate Medicine 10:37 a.m. Oct. 10, 2014 - benzinga.com
Orexigen On A Tear - In The Wrong Direction 1:10 a.m. Oct. 7, 2014 - Seeking Alpha
Belviq Sales Flat - Model Your Expectations 6:44 p.m. Oct. 3, 2014 - Seeking Alpha
A Look At Arena's Other Drug 4:37 p.m. Oct. 3, 2014 - Seeking Alpha
Premature Combination Use Of Belviq And Phentermine Is A Risk 9:27 a.m. Sept. 28, 2014 - Seeking Alpha
Arena Pharmaceuticals (ARNA) on NewsMakers in the Biotech Industry Conference Call Transcript 2:22 p.m. Sept. 26, 2014 - Seeking Alpha
Belviq Sales Benefit From Advertising - Up 2.8% 12:16 p.m. Sept. 26, 2014 - Seeking Alpha
Belviq Advertising Sees Major Push - The Equity May See It As Well 5:25 p.m. Sept. 22, 2014 - Seeking Alpha
Belviq Sales Recover From Holiday Dip 5:06 p.m. Sept. 21, 2014 - Seeking Alpha
A Deeper Look At Belviq And Phentermine - Why Investors Need To Model Expectations 12:08 p.m. Sept. 19, 2014 - Seeking Alpha
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume 10:04 a.m. Sept. 19, 2014 - TheStreet.com
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape 9:11 a.m. Sept. 19, 2014 - Zacks.com
It Takes Less Than 15 Minutes To Buy VVUS Shares! 8:51 a.m. Sept. 19, 2014 - Seeking Alpha
Belviq And Phentermine Study Awes Some Investors - Should It? 10:00 a.m. Sept. 17, 2014 - Seeking Alpha
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 9:30 a.m. Oct. 17, 2014 - PR Newswire - PRF
Global Anti-Obesity Drugs Market 5:07 p.m. Oct. 16, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine 11:36 a.m. Oct. 10, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 8:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 8:40 a.m. Sept. 12, 2014 - PR Newswire - PRF
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 8:00 a.m. Sept. 2, 2014 - PR Newswire - PRF
Post-Earnings Review and Highlights - Arena Pharma 9:30 a.m. Aug. 11, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4:30 a.m. Aug. 1, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 8:00 a.m. July 30, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category 8:00 a.m. July 29, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 8:00 a.m. July 25, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel 8:00 a.m. July 21, 2014 - PR Newswire - PRF
Cannabis Based Healing Products Lead Commercialization For Medical Marijuana Patients - Company Introduces New Edible CBD-Rich Product Line 8:30 a.m. July 16, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office 4:31 p.m. July 15, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV 8:00 a.m. July 10, 2014 - PR Newswire - PRF
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma 7:20 a.m. July 10, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference 8:00 a.m. June 13, 2014 - PR Newswire - PRF
Dosing Initiation, Conferences Participation, Trial Results Publication, and Financial Results - Analyst Notes on Arena, Acceleron Pharma, HealthSouth, The Medicines Company and Taro 5:40 a.m. June 10, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Initiates Phase 1b Clinical Trial of APD334 for Autoimmune Diseases 8:00 a.m. June 3, 2014 - PR Newswire - PRF
(0)
(0)